Azacitidine
Nodal T-Follicular Helper Cell Lymphoma, Follicular Type
Explore 16 assets in Nodal T-Follicular Helper Cell Lymphoma, Follicular Type →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Alliance for Clinical Trials in Oncology
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04803201CT.gov Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | — | Suspended | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Nodal T-Follicular Helper Cell Lymphoma, Follicular Type
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Azacitidine (this asset) | Alliance for Clinical Trials in Oncology | P2 | CCC · 53 |
| Pralatrexate | Corvus Pharmaceuticals, Inc. | P3 | BB |
| Nivestim | City of Hope Medical Center | P3 | B |
| Soquelitinib | Corvus Pharmaceuticals, Inc. | P3 | B |
| Pembrolizumab | Northwestern University | P2 | B |
| Prednisone | City of Hope Medical Center | P2 | B |
| (+)-Vincristine | City of Hope Medical Center | P2 | B |
| Cyclophosphamide | City of Hope Medical Center | P2 | B |
| Belinostat | Corvus Pharmaceuticals, Inc. | P3 | B |
+10 more in the Nodal T-Follicular Helper Cell Lymphoma, Follicular Type cohort
Other indications for Azacitidine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BBB · 73 |
| Acute Erythroid Leukemia | — | P2 | BB · 71 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Azacitidine in Nodal T-Follicular Helper Cell Lymphoma, Follicular Type. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/azacitidine-nodal-t-follicular-helper-cell-lymphoma-follicular-type
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →